TY - JOUR
T1 - Predictors of coronary artery calcium incidence and progression
T2 - The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)
AU - Cardoso, Rhanderson
AU - Generoso, Giuliano
AU - Staniak, Henrique L.
AU - Foppa, Murilo
AU - Duncan, Bruce B.
AU - Pereira, Alexandre C.
AU - Blaha, Michael J.
AU - Blankstein, Ron
AU - Nasir, Khurram
AU - Bensenor, Isabela M.
AU - Lotufo, Paulo A.
AU - Bittencourt, Marcio S.
N1 - Funding Information:
The ELSA-Brasil baseline study was supported by the Brazilian Ministry of Health (Science and Technology Department) and the Brazilian Ministry of Science and Technology ( Financiadora de Estudos e Projetos and CNPq National Research Council; grants 01 06 0010.00 RS , 01 06 0212.00 BA , 01 06 0300.00 ES , 01 06 0278.00 MG , 01 06 0115.00 SP , and 01 06 0071.00 RJ ). The ancillary ELSA-Brasil CAC was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo ( FAPESP 2011/12256-4 ).
Funding Information:
Dr. Marcio Bittencourt is supported by a grant from Sanofi and has received speaker fees from GE Healthcare and Boston Scientific . All other authors report no conflict of interests.
Funding Information:
The ELSA-Brasil baseline study was supported by the Brazilian Ministry of Health (Science and Technology Department) and the Brazilian Ministry of Science and Technology (Financiadora de Estudos e Projetos and CNPq National Research Council; grants 01 06 0010.00 RS, 01 06 0212.00 BA, 01 06 0300.00 ES, 01 06 0278.00 MG, 01 06 0115.00 SP, and 01 06 0071.00 RJ). The ancillary ELSA-Brasil CAC was funded by Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo (FAPESP 2011/12256-4).Dr. Marcio Bittencourt is supported by a grant from Sanofi and has received speaker fees from GE Healthcare and Boston Scientific. All other authors report no conflict of interests.
Publisher Copyright:
© 2020 Elsevier B.V.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9
Y1 - 2020/9
N2 - Background and aims: There are limited data on serial coronary artery calcium (CAC) assessments outside North American and European populations. We sought to investigate risk factors for CAC incidence and progression in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Methods: We included individuals with no prior cardiovascular disease and two CAC measurements in ELSA-Brasil. Incident CAC was defined as a baseline CAC of 0 followed by CAC >0 on the second study. CAC progression was defined according to multiple published criteria. We performed logistic and linear regression to identify risk factors for CAC incidence and progression. We also examined risk factor effect modification by baseline CAC (0 vs. >0). Results: A total of 2707 individuals were included (57% women, age 48.6 ± 7.7 years). Participants self-identified as white (55%), brown (24%), black (16%), Asian (4%) and Indigenous (1%). The mean period between CAC assessments was 5.1 ± 0.9 years. CAC incidence occurred in 282 (13.3%) of 2127 individuals with baseline CAC of 0. CAC progression occurred in 319 (55%) of 580 participants with baseline CAC >0. Risk factors for CAC incidence included older age, male sex, white race, hypertension, diabetes, higher BMI, smoking, lower HDL-C, higher LDL-C and triglycerides, and metabolic syndrome. Older age and elevated LDL-C were associated with CAC incidence, but not progression. Risk factors consistently associated with CAC progression were hypertension, diabetes, hypertriglyceridemia, and metabolic syndrome. On interaction testing, these four risk factors were more strongly associated with CAC progression as compared to CAC incidence. Conclusions: CAC incidence was associated with multiple traditional risk factors, whereas the only risk factors associated with progression of CAC were hypertension, diabetes, hypertriglyceridemia, and metabolic syndrome.
AB - Background and aims: There are limited data on serial coronary artery calcium (CAC) assessments outside North American and European populations. We sought to investigate risk factors for CAC incidence and progression in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Methods: We included individuals with no prior cardiovascular disease and two CAC measurements in ELSA-Brasil. Incident CAC was defined as a baseline CAC of 0 followed by CAC >0 on the second study. CAC progression was defined according to multiple published criteria. We performed logistic and linear regression to identify risk factors for CAC incidence and progression. We also examined risk factor effect modification by baseline CAC (0 vs. >0). Results: A total of 2707 individuals were included (57% women, age 48.6 ± 7.7 years). Participants self-identified as white (55%), brown (24%), black (16%), Asian (4%) and Indigenous (1%). The mean period between CAC assessments was 5.1 ± 0.9 years. CAC incidence occurred in 282 (13.3%) of 2127 individuals with baseline CAC of 0. CAC progression occurred in 319 (55%) of 580 participants with baseline CAC >0. Risk factors for CAC incidence included older age, male sex, white race, hypertension, diabetes, higher BMI, smoking, lower HDL-C, higher LDL-C and triglycerides, and metabolic syndrome. Older age and elevated LDL-C were associated with CAC incidence, but not progression. Risk factors consistently associated with CAC progression were hypertension, diabetes, hypertriglyceridemia, and metabolic syndrome. On interaction testing, these four risk factors were more strongly associated with CAC progression as compared to CAC incidence. Conclusions: CAC incidence was associated with multiple traditional risk factors, whereas the only risk factors associated with progression of CAC were hypertension, diabetes, hypertriglyceridemia, and metabolic syndrome.
KW - Cardiovascular risk factors
KW - Coronary artery calcium
KW - Incidence
KW - Progression
UR - http://www.scopus.com/inward/record.url?scp=85089733860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089733860&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2020.07.003
DO - 10.1016/j.atherosclerosis.2020.07.003
M3 - Article
C2 - 32858396
AN - SCOPUS:85089733860
SN - 0021-9150
VL - 309
SP - 8
EP - 15
JO - Atherosclerosis
JF - Atherosclerosis
ER -